Effects of Adriamycin-Cytoxan chemotherapy on hematological and electrolyte parameters among breast cancer patients

BACKGROUND: Adriamycin-Cytoxan (AC) is a common chemotherapy treatment for breast cancer (BC) patients. Its electrolyte and hematological adverse effects have not been addressed adequately. OBJECTIVE: This study aimed to assess the effect of AC on hematological and electrolyte parameters among BC pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Tadesse, Fikremariam Abiye, Leminie, Abebaye Aragaw
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10185890/
https://www.ncbi.nlm.nih.gov/pubmed/37205205
http://dx.doi.org/10.3389/fonc.2023.1103013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10185890/
https://www.ncbi.nlm.nih.gov/pubmed/37205205
http://dx.doi.org/10.3389/fonc.2023.1103013

Ejemplares similares